NKTR
NASDAQ HealthcareNektar Therapeutics - Common Stock
Biotechnology
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
�� 市场数据
| 价格 | $58.56 |
|---|---|
| 成交量 | 2,068,994 |
| 市值 | 1.98B |
| 贝塔系数 | 1.250 |
| RSI（14日） | 8.1 超卖 |
| 200日均线 | $58.89 |
| 50日均线 | $77.35 |
| 52周最高 | $109.00 |
| 52周最低 | $7.99 |
| Forward P/E | -4.66 |
| Price / Book | 2.51 |
🎯 投资策略评分
NKTR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (93/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (20/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 NKTR in your text
粘贴任何文章、记录或帖子 — 工具将提取 NKTR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.